AstraZeneca’s (AZN) Fasenra has been approved in the European Union, EU, as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis, EGPA. EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and was based on positive results from the MANDARA Phase III trial, published in The New England Journal of Medicine. In the trial, nearly 60% of Fasenra-treated patients achieved remission, which was comparable to mepolizumab-treated patients.3 Data also showed 41% of Fasenra-treated patients fully tapered off oral corticosteroids.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Eccogene receives milestone payment of $60M from AstraZeneca
- CytoSorbents announces FDA has accepted De Novo medical device application
- Ionis Pharmaceuticals announces CHMP recommends approval for Wainzua
- Hutchmed announces results from SAVANNAH trial
- AstraZeneca, Daiichi Sankyo announces Enhertu approved in China